ArticleThe journal of histochemistry and cytochemistry : official journal of the Histochemistry Society2017
The Probiotic VSL#3 Modulates Colonic Macrophages, Inflammation, and Microflora in Acute Trinitrobenzene Sulfonic Acid Colitis.
Article in The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- Probiotics reduce the severity of DSS-induced colitis in aged mice by enhancing intestinal barrier function and modulating gut microbiota.GeroScience · 2026Article
- Nfil3 integrates circadian rhythm and microbial metabolite signaling to maintain gut-liver immune-metabolic homeostasis under high-fat diet stress.Journal of translational medicine · 2026Article
- Enhanced Macrophage and Granulocytic Recruitment with Increased Neo-Angiogenesis in Chicken Embryo Yolk Sac Following In Ovo Probiotic Blend Administration.Veterinary sciences · 2025Article
- Probiotic and Vitamin D Ameliorate TNBS-Induced Colitis by Targeting Mucosal Barrier and Neutrophil Infiltration.Nutrients · 2025Article
- Implication of the enteric glia in the IBS-like colonic inflammation associated with endometriosis.BMC women's health · 2024Article
- Gut Microbiome-Colorectal Cancer Relationship.Microorganisms · 2024Review
- Mechanistic insights into the role of probiotics in modulating immune cells in ulcerative colitis.Immunity, inflammation and disease · 2023Review
- Regulation of gut microbiota-bile acids axis by probiotics in inflammatory bowel disease.Frontiers in immunology · 2022Review
- COVID-19 Impact on Public Health, Environment, Human Psychology, Global Socioeconomy, and Education.TheScientificWorldJournal · 2022Review
- Evolutionary Insights Into Microbiota Transplantation in Inflammatory Bowel Disease.Frontiers in cellular and infection microbiology · 2022Review
- Probiotics: A potential immunomodulator in COVID-19 infection management.Nutrition research (New York, N.Y.) · 2021Review
- The Influence of Probiotics on the Firmicutes/Bacteroidetes Ratio in the Treatment of Obesity and Inflammatory Bowel disease.Microorganisms · 2020Review
- Macrophage Polarization Induced by Probiotic Bacteria: a Concise Review.Probiotics and antimicrobial proteins · 2020Review
- Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases.World journal of clinical cases · 2020Review
- Probiotic Mixture VSL#3 Alleviates Dextran Sulfate Sodium-induced Colitis in Mice by Downregulating T Follicular Helper Cells.Current medical science · 2019Article
- Claudin Family Participates in the Pathogenesis of Inflammatory Bowel Diseases and Colitis-Associated Colorectal Cancer.Frontiers in immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
The probiotic mixture VSL#3 attenuates colitis in patients with Inflammatory Bowel Disease (IBD) and in animal models of this condition, but the mechanisms involved are incompletely understood. VSL#3 alters macrophage morphology and secretory profile in vitro in a polarization-dependent manner. We examined the effect of VSL#3 on macrophages in acute trinitrobenzene sulfonic acid-induced colitis. Rats were randomized to normal, colitis, or colitis+VSL#3 groups. After sacrifice, the colons were evaluated for macroscopic and microscopic damage. Serum cytokine levels were measured, and microbiome analysis undertaken. Total and M1 colonic macrophages, and total and proliferating hepatic macrophages were assessed by double immunofluorescence staining. Colitis+VSL#3 rats had lower macroscopic damage, with less microscopic damage in the proximal colon, compared with colitis alone. Colitis significantly increased colonic macrophage infiltration, which was significantly reduced by VSL#3 treatment. VSL#3 did not decrease the colitis-induced surge of colonic M1 macrophages or hepatic macrophages. VSL#3 reduced colitis-induced serum cytokine levels, and induced restoration of colonic transcript levels for pro-inflammatory, anti-inflammatory, and barrier proteins to, or past, normal levels. Fecal bacteria distribution changed between groups. In summary, the probiotic VSL#3 reduces colitis severity, colonic macrophage infiltration, and serum cytokine levels, but does not dampen the pro-inflammatory phenotype of M1 macrophages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.